A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody
Conditions
- Lung Cancer
- TKI Resistance
- EGFR Sensitive Mutation
- Anlotinib
- Pianzumab
Interventions
- DRUG: Anlotinib
- DRUG: Penpulimab
Sponsor
Degan Lu
Collaborators